Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Gelrode – page 70

1 989 clinical trials in Gelrode, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Gelrode at a glance
1 989
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 989 trials in Gelrode

Open in trial search

Systemic lupus erythematosus+1

Not yet recruiting

Study of CC-97540 CD19-targeted CAR T cells in patients with systemic lupus erythematosus who did not respond to previous immunosuppressive treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.

Bronchiectasis

Not yet recruiting

Study of Nebulized Human Normal Immunoglobulin (CSL787) for Adults with Non-cystic Fibrosis Bronchiectasis to Find Best Dose and Test Safety

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:CSL Behring LLC

Fallopian tube cancer+1

Not yet recruiting

Study of TORL-1-23 and pegfilgrastim in women with advanced platinum-resistant ovarian, peritoneal, or fallopian tube cancer expressing CLDN6

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate
  • Sponsor:Torl Biotherapeutics LLC

Medulloblastoma

Not yet recruiting

Comparing two treatment regimens with drug combination for newly diagnosed low-risk medulloblastoma to evaluate cognitive function outcomes

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:GPOH gGmbH

Cardiac failure+5

Not yet recruiting

Study of cardiac atrial stem cells injected into heart muscle for treating advanced heart failure in patients with prior heart attack and reduced heart function

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:CASCS
  • Sponsor:CASC8

Colitis ulcerative

Not yet recruiting

Study on the Safety and Effectiveness of OD-07656 and Vedolizumab for Patients with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Vedolizumab
  • Sponsor:Odyssey Therapeutics Inc.

Gastrointestinal disorder

Not yet recruiting

Study on the Safety and Effects of Orziloben (NST-6179) for Patients with Intestinal Failure-Associated Liver Disease

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Orziloben
  • Sponsor:NorthSea Therapeutics B.V.

Loss of consciousness

Not yet recruiting

Study on Zolpidem's Effects in Patients with Vision Impairments, Disorders of Consciousness, and Neurotypical Volunteers

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Mannitol
  • Sponsor:Universite De Liege

COVID-19

Not yet recruiting

Study on COVID-19 Immunity in Immunocompromised Adults Using Raxtozinameran and Bretovameran in Belgium

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Bretovameran
  • Sponsor:Sciensano

Autism spectrum disorder

Not yet recruiting

Study on Improving Social Interaction in Children with Autism Using Oxytocin Nasal Spray and Therapy

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · Healthy volunteers
  • Substances:Oxytocin
  • Sponsor:UZ Leuven

Arteriovenous malformation

Not yet recruiting

Study on the Safety and Effectiveness of Regorafenib for Patients with Arterio-Venous Malformations Unresponsive to Standard Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Regorafenib
  • Sponsor:Cliniques Universitaires Saint-Luc

Study on Datopotamab Deruxtecan and Rilvegostomig for Stage I Non-Small Cell Lung Cancer Patients with ctDNA-Positive or High-Risk Features

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Gelrode

What the registry says about research in the country

01 Gastroenterology Research

Clinical trials focusing on optimizing treatment strategies for patients with functional dyspepsia and related gastrointestinal conditions. Research evaluates various approaches to medication management, particularly in the context of proton pump inhibitor usage.

  • Medication De-prescribing Strategies
  • Gastrointestinal Health Management
  • Treatment Optimization

This primary care research aims to improve patient outcomes by identifying the most effective methods for managing chronic medication use in digestive conditions.

02 Primary Care Innovation

Studies examining innovative approaches to managing common digestive symptoms like heartburn and reflux. The research explores alternative treatment methods and medication management strategies in primary care settings.

  • Patient-Centered Care Approaches
  • Alternative Treatment Methods
  • Long-term Medication Management

These trials aim to establish evidence-based protocols for optimizing long-term medication use in primary care practice.

03 Therapeutic Strategies

Investigation of comparative effectiveness between different therapeutic approaches, including on-demand medication use and alternative formulations for managing digestive conditions.

  • Comparative Treatment Effectiveness
  • Medication Reduction Strategies
  • Quality of Life Outcomes

The research focuses on developing evidence-based strategies for medication optimization while maintaining effective symptom control.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.